Category: Research/Reports

340B Small Share of Drugmaker Revenue, Says Hospital-Backed Report

March 14, 2024 Rich Daly, Editor in Chief Views

340B drug discounts only amounted to a small percentage of total drugmaker revenue, a hospital-funded study found.

Despite the increase in the amount of 340B program drug discounts, those only amounted to 3.1% of global and 7% [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

U.C. Berkeley Researcher Proposes 340B Be Limited to the Indigent or that Providers Pass on their Discounts to Insurance Industry

March 14, 2024 Rich Daly, Editor in Chief Views

Dr. James Robinson, a health economist at University of California at Berkley, criticized hospitals’ “buy and bill” drug acquisition process.

A University of California at Berkeley academic is proposing a series of major reforms to the 340B discount drug program [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

DSH Hospitals Are Using 340B in ‘Margin-Motivated Ways,’ Says Research Review

February 27, 2024 Rich Daly, Editor in Chief Views

A recent Milbank Quarterly research review suggested DSH hospitals participate in 340B in "margin-motivated ways."

The highest-quality evidence from published 340B research indicates nonprofit, disproportionate share hospitals may be using the 340B program in margin-motivated [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

PhRMA Washington Post Advertorial Highlights Data Critical of 340B Program

February 21, 2024 Rich Daly, Editor in Chief Views

A pharmaceutical industry advertorial in the Washington Post questioned whether the 340B program benefited hospital patients.

The leading advocacy group for pharmaceutical manufacturers recently published an advertorial in the Washington Post that highlights a range of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

AHA Pans NEJM Study on 340B Price Mark Ups, Lead Author Fires Back

February 13, 2024 Rich Daly, Editor in Chief Views

Aimee Kuhlman, vice president of advocacy and grassroots for AHA, co-wrote a blog post that criticized an NEJM study on 340B price mark ups.

The country’s largest hospital advocacy organization has leveled several challenges to a high-profile January study that concluded 340B hospitals had [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B Hospitals Had Largest Markups of High-Cost Infused Drugs: Study

January 30, 2024 Rich Daly, Editor in Chief Views

A New England Journal of Medicine study found that 340B hospitals had larger price markups than other hospitals or physician practices for certain high-cost infusion drugs.

340B hospitals had larger price markups than other hospitals or physician practices for 57 high-cost infusion drugs, according to a [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Critics of 340B Urge Congressional Reforms of the Program

December 21, 2023 Rich Daly, Editor in Chief Views

Edolphus Towns, Jr., a former congressman (D-N.Y.) who voted to create the 340B program, recently wrote a guest editorial calling for congressional reforms.

Critics of the 340B program, including a former congressman who voted to create the program, have written recent editorials urging [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B Reforms Needed, Says Former Presidential Candidate, Drug Industry Consultant

December 5, 2023 Rich Daly, Editor in Chief Views

Howard Dean, a former Democratic presidential candidate who has consulted for the drug industry, said the 340B program is in need of reforms.

The 340B program has become “a multibillion-dollar boondoggle for hospital mega-chains” and needs reform, says Howard Dean, a one-time Democratic [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B Provides Benefits, Needs Reform, Says Literature Review

November 28, 2023 Tom Mirga, Editor at Large Views

A JAMA Health Network literature review found that the 340B program provides a range of benefits but needs reforms.

The 340B program has provided a range of benefits but also needs reforms, according to a recent review of published [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B’s Footprint in Medicare Part D Is Growing, Study Says

November 28, 2023 Tom Mirga, Editor at Large Views

A JAMA Health Forum study co- authored by Sean Dickson found the 340B program's footprint in Medicare Part D is increasing.

340B covered entities captured nearly half (49.9%) of their 340B-eligible prescriptions billed to Medicare Part D in 2020, up from [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Site Footer Live